



7TH DUTCH BREAST PATHOLOGY COURSE

'Preventing overtreatment of breast cancer precursors'

Wednesday 7 & Thursday 8 November 2018

Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam



Since the introduction of screening strategies, the incidence of Ductal Carcinoma In Situ (DCIS) has increased manifold, without a decrease in the incidence of advanced stages of breast cancer. This suggests that many DCIS lesions are detected that would have never caused any clinical symptoms if screening would have been omitted. This so-called overdiagnosis results in overtreatment, as we cannot distinguish yet which DCIS lesions are harmless and which ones potentially hazardous. As a consequence, many women with DCIS lesions carry the burden of ineffective, needless treatment.

To conquer this, pathologists should try to find and validate features that improve our risk stratification for each individual woman with DCIS.

This international 'Dutch Breast Pathology Course' aims to explore our possibilities, challenges, and limitations in diagnosing and classifying breast cancer precursor lesions in the clinical context. Therefore, input will and has to be provided by different disciplines as well, i.e. epidemiology, radiology, surgery, radiotherapy and the patient perspective.

To achieve all this, we intend to encourage you to practice, interact, discuss, and come up with your ideas how to solve this breast cancer precursor dilemma. We look very much forward to embark with you on this challenging mission.

Programme at a glance

Detection, diagnostics and treatment of breast precursor lesions will be discussed in depth in relation to the prevention of overtreatment, including the relevance of precursor lesions in the low-grade spectrum, patient perspectives on treatment decisions and current trials on DCIS. The issue of interobserver variability will be highlighted and interactively discussed for improvement of our current classification system.

Before the course we would like each participating pathologist to review 150 DCIS cases using digitized whole slides (8 hours) with an easy to use digital scoring system. For both the pathological review and the course accreditation is requested separately. In addition all pathologists finishing reviewing these cases will become co-author of the final analysis.

FACULTY

Wednesday 7 & Thursday 8 November 2018

Drs. Emilie Groen, MD.

Consultant breast pathologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Prof. Laura Collins, MD. PhD.

Consultant breast pathologist, Beth Israel Deaconess Medical Center, Boston, United States of America

Prof. Paul van Diest, MD. PhD.

Consultant breast pathologist, University Medical Center Utrecht, the Netherlands

Prof. Sarah Pinder, MD. PhD.

Consultant breast pathologist, King's College – Guy's Hospital, London, UK

Prof. Ruud Pijnappel, MD. PhD.

Screening radiologist & director of the national screening reference center, University Medical Center Utrecht, the Netherlands

Prof. Harry de Koning, PhD.

Epidemiologist & professor of evaluation of screening, Erasmus Medical Center, Rotterdam, the Netherlands

Dr. Jos Bart, MD. PhD.

Breast pathologist, Universitair Medisch Centrum Groningen, Groningen, the Netherlands & Isala Zwolle, Zwolle, the Netherlands

Dr. Willem Vreuls, MD.

General pathologist, Canisius-Wilhelmina Ziekenhuis, Nijmegen, the Netherlands

Mr. Dr. Frederieke van Duijnhoven, MD. PhD.

Breast surgical oncologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Dr. Paula Elkhuizen, MD. PhD.

Breast radiation oncologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Dr. Gabe Sonke, MD. PhD.

Medical oncologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Drs. Lindy Visser, MSc.

Molecular biologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Prof. Jelle Wesseling, MD. PhD.

Consultant breast pathologist, Antoni van Leeuwenhoek – Netherlands Cancer Institute, Amsterdam, the Netherlands

Mr. Ellen Verschuur-van der Voort

Verschuur Advocatuur - Patient Advocate, Bloemendaal, the Netherlands

PROGRAMME

Wednesday 7 November 2018

09.00-09.45

Registration

09.45-10.00

Welcome

10.00-11.00

Lesions of the Low Grade Breast
Neoplasia Pathway.

Prof. Laura Collins, MD. PhD.

11.00-12.00

Variation of DCIS grading in the
Netherlands and its clinical impact.

Prof. Paul van Diest, MD. PhD.

12.00-13.00

Lunch break

13.00-14.00

Results from our interobserver analysis
study, do we agree?

Drs. Emilie Groen, MD.

14.00-15.00

Panel discussion: breast cancer
precursors: to split or to lump, that's
the question?

Prof. Laura Collins, MD. PhD.,
Prof. Paul van Diest, MD. PhD.,
Dr. Jos Bart, MD. PhD. and
Dr. Willem Vreuls, MD.

15.00-15.30

Coffee break

15.30-16.30

Is it safe to leave out treatment for
DCIS?

Prof. Sarah Pinder, MD. PhD.

16.30-17.30

How can we solve the DCIS dilemma?
Prof. Jelle Wesseling, MD. PhD.

17.30

Dinner

PROGRAMME

Thursday 8 November 2018

08.30-09.30

Surgical approach to DCIS, how to minimize damage?

Mr. Dr. Frederieke van Duijnhoven, MD. PhD.

09.30-10.30

Radiotherapeutical approach to DCIS, how to minimize damage?

Dr. Paula Elkhuizen, MD. PhD.

10.30-11.00

Coffee break

11.00-11.45

What do women think about DCIS and how do they choose their optimal treatment?

Mr. Ellen Verschuur-van der Voort

11.45-12.30

Is there a role for hormonal treatment in DCIS?

Dr. Gabe Sonke, MD. PhD.

12.30-13.30

Lunch break

13.30-14.30

How to distinguish harmless from hazardous DCIS?

Drs. Lindy Visser, MSc.

14.30-15.30

Potentials, limitations and challenges of breast cancer screening, a radiologist's perspective.

Prof. Ruud Pijnappel, MD. PhD.

15.30-16.00

Coffee break

16.00-17.00

The benefit of breast cancer screening: what about early lesions?

Prof. Harry de Koning, PhD.

GENERAL INFORMATION

When

Wednesday 7 & Thursday 8 November 2018

Venue

The Netherlands Cancer Institute –
Antoni van Leeuwenhoek
Conference Room Z4
Plesmanlaan 121
1066 CX AMSTERDAM, the Netherlands

Target audience

Pathologists and pathology residents
in the final year of their training

Registration

Registration exclusively via the online
registration form:

<https://symposium.nki.nl/dbpc.aspx>

Registration deadline

Saturday 1 September 2018

Fees

Pathologists € 750,-

Pathology residents € 350,-

The fee includes internet access, material,
lunch, coffee and tea during breaks as well
as dinner on Wednesday 7 November 2018.

Accreditation

All participants will receive a certificate as
evidence of their attendance. Accreditation
will be arranged via the Dutch Society
for Pathology. To be eligible for CME
accreditation, students must participate in
the interobserver study and attend the two
day course.

Language

The official language of the course is
English.

More information

For more information and/or
questions regarding your registration,
please contact Sabine de Groot
+31 (0) 20 512 7872
s.d.groot@nki.nl